Han Liu1,2, Junchi He1, Yue Wu1, Yang Du3,4, Yinghua Jiang1,4, Chengzhi Chen5, Zhanyang Yu4, Jianjun Zhong1, Zhigang Wang2, Chongjie Cheng1, Xiaochuan Sun1, Zhijian Huang1. 1. Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of Neurosurgery, Qilu Hospital of Shandong University (Qingdao Campus), Qingdao, China. 3. Department of Neurology, Xiangya Hospital, Central South University, Changsha, China. 4. Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 5. Department of Occupational and Environmental Health, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, China.
Abstract
BACKGROUND AND TARGET: Following brain trauma, blood-brain barrier (BBB) disruption and inflammatory response are critical pathological steps contributing to secondary injury, leading to high mortality and morbidity. Both pathologies are closely associated with endothelial remodeling. In the present study, we concentrated on annexin A1 (ANXA1) as a novel regulator of endothelial function after traumatic brain injury. METHODS: After establishing controlled cortical impact (CCI) model in male mice, human recombinant ANXA1 (rANXA1) was administered intravenously, followed by assessments of BBB integrity, brain edema, inflammatory response, and neurological deficits. RESULT: Animals treated with rANXA1 (1 μg/kg) at 1 h after CCI exhibited optimal BBB protection including alleviated BBB disruption and brain edema, as well as endothelial junction proteins loss. The infiltrated neutrophils and inflammatory cytokines were suppressed by rANXA1, consistent with decreased adhesive and transmigrating molecules from isolated microvessels. Moreover, rANXA1 attenuated the neurological deficits induced by CCI. We further found that the Ras homolog gene family member A (RhoA) inhibition has similar effect as rANXA1 in ameliorating brain injuries after CCI, whereas rANXA1 suppressed CCI-induced RhoA activation. CONCLUSION: Our findings suggest that the endothelial remodeling by exogenous rANXA1 corrects BBB disruption and inflammatory response through RhoA inhibition, hence improving functional outcomes in CCI mice.
BACKGROUND AND TARGET: Following brain trauma, blood-brain barrier (BBB) disruption and inflammatory response are critical pathological steps contributing to secondary injury, leading to high mortality and morbidity. Both pathologies are closely associated with endothelial remodeling. In the present study, we concentrated on annexin A1 (ANXA1) as a novel regulator of endothelial function after traumatic brain injury. METHODS: After establishing controlled cortical impact (CCI) model in male mice, human recombinant ANXA1 (rANXA1) was administered intravenously, followed by assessments of BBB integrity, brain edema, inflammatory response, and neurological deficits. RESULT: Animals treated with rANXA1 (1 μg/kg) at 1 h after CCI exhibited optimal BBB protection including alleviated BBB disruption and brain edema, as well as endothelial junction proteins loss. The infiltrated neutrophils and inflammatory cytokines were suppressed by rANXA1, consistent with decreased adhesive and transmigrating molecules from isolated microvessels. Moreover, rANXA1 attenuated the neurological deficits induced by CCI. We further found that the Ras homolog gene family member A (RhoA) inhibition has similar effect as rANXA1 in ameliorating brain injuries after CCI, whereas rANXA1 suppressed CCI-induced RhoA activation. CONCLUSION: Our findings suggest that the endothelial remodeling by exogenous rANXA1 corrects BBB disruption and inflammatory response through RhoA inhibition, hence improving functional outcomes in CCI mice.
Authors: Bin Huang; Paul R Krafft; Qingyi Ma; William B Rolland; Basak Caner; Tim Lekic; Anatol Manaenko; Mai Le; Jiping Tang; John H Zhang Journal: Neurobiol Dis Date: 2012-01-24 Impact factor: 5.996
Authors: Ajmal Zemmar; Oliver Weinmann; Yves Kellner; Xinzhu Yu; Raul Vicente; Miriam Gullo; Hansjörg Kasper; Karin Lussi; Zorica Ristic; Andreas R Luft; Mengia Rioult-Pedotti; Yi Zuo; Marta Zagrebelsky; Martin E Schwab Journal: J Neurosci Date: 2014-06-25 Impact factor: 6.167
Authors: Song Zhao; Zhanyang Yu; Yu Liu; Yang Bai; Yinghua Jiang; Klaus van Leyen; Yong-Guang Yang; Josephine M Lok; Michael J Whalen; Eng H Lo; Xiaoying Wang Journal: Neurosci Lett Date: 2016-12-05 Impact factor: 3.046
Authors: Thomas Gattringer; Maria Valdes Hernandez; Anna Heye; Paul A Armitage; Stephen Makin; Francesca Chappell; Daniela Pinter; Fergus Doubal; Christian Enzinger; Franz Fazekas; Joanna M Wardlaw Journal: Transl Stroke Res Date: 2019-11-08 Impact factor: 6.829
Authors: Niels Heemskerk; Lilian Schimmel; Chantal Oort; Jos van Rijssel; Taofei Yin; Bin Ma; Jakobus van Unen; Bettina Pitter; Stephan Huveneers; Joachim Goedhart; Yi Wu; Eloi Montanez; Abigail Woodfin; Jaap D van Buul Journal: Nat Commun Date: 2016-01-27 Impact factor: 14.919